Focus on Drug Approvals. The FDA has approved Syndax Pharmaceuticals’ Revumenib (SNDX-5613, inhibitor of menin-KMT2A interaction) for relapsed or refractory acute leukemia with lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
Focus Biomolecules can supply SNDX-5613 for research applications. Contact us for more information.
